Clinical Trials Directory

Trials / Unknown

UnknownNCT04500379

Reliability and Validity of FIBSER, STAR-P, HEA Scale The Reliability and Validity of Chinese Version of FIBSER, STAR-P, HEA Scale in Depression Assessment

The Reliability and Validity of Chinese Version of FIBSER, STAR-P, HEA Scale in Depression

Status
Unknown
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
Shanghai Mental Health Center · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

According to the survey of the World Health Organization, the number of patients with depression in the world has reached 350 million, has becoming the primary cause of disability and the main disease burden worldwide. In order to better dealing with adverse reactions, improving the doctor-patient relationship and optimizing the treatment cost, FIBSER, STAR-P and HEA Health Economics Follow-up Evaluation Scale are selected as simple and quick evaluation scales to evaluate the influence, doctor-patient relationship and social and economic benefits after drug treatment in clinical treatment. At present, the reliability and validity of FIBSER, STAR-P and HEA scales will be verified the reliability and validity of the above three scales in depressive disorder, aiming at enriching the treatment of depressive patients based on assessment, thus improving the compliance of medication for depressive disorder, improving the doctor-patient relationship and reducing the total burden of social diseases.

Detailed description

In this study, the reliability and validity of FIBSER Scale, Doctor-patient Relationship Scale-Patient Edition (STAR-P) and HEA in Chinese population will be verified to increase the diversity and selectivity of domestic assessment tools. This study includes two steps. 1. baseline: demographic data, HAM-D, HAM-A, YMRS, drug side effects scale:FIBSER, TESS; doctor-patient relationship scale :STAR-P, PDRQ-15;Health economics follow-up evaluation scale :SDS and HEA were evaluated. 2. follow-up (4 weeks): HAM-D, HAM-A, YMRS, FIBSER, STAR-P and HEA scale in order to verify the reliability of retest.

Conditions

Timeline

Start date
2020-07-24
Primary completion
2021-10-05
Completion
2022-12-28
First posted
2020-08-05
Last updated
2022-09-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04500379. Inclusion in this directory is not an endorsement.